乳腺癌患者辅助治疗中 TYMS、MTHFR、p53 和 MDR1 基因多态性。
TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.
机构信息
Clinical Science Department, Universidad de Las Palmas de Gran Canaria, Spain.
出版信息
Cancer Epidemiol. 2010 Aug;34(4):490-3. doi: 10.1016/j.canep.2010.03.004. Epub 2010 Apr 3.
PURPOSE
The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy.
RESULTS
Observed allelic frequencies were: TSER, (2) 0.55 and (3) 0.45; MTHFR C677T, (C) 0.65 and (T) 0.35; p53 Arg72Pro, (Arg) 0.76 and (Pro) 0.24; MDR1 C3435T, (C) 0.51 and (T) 0.49. MTHFR C677T was found to be a strong predictor of the presence of multifocal tumour (odds ratio, 4.1; 95% CI, 1.1-15.7; P=0.035).
CONCLUSION
Our data indicate that breast cancer patients with the C/C variant may present multifocal tumour most frequently.
目的
研究 80 例接受辅助化疗的乳腺癌患者 TSER（TYMS）、C677T（MTHFR）、Arg72Pro（p53）和 C3435T（MDR1）基因多态性的分布。
结果
观察到的等位基因频率为：TSER，（2）0.55 和（3）0.45；MTHFR C677T，（C）0.65 和（T）0.35；p53 Arg72Pro，（Arg）0.76 和（Pro）0.24；MDR1 C3435T，（C）0.51 和（T）0.49。MTHFR C677T 被发现是多灶性肿瘤存在的强预测因子（比值比，4.1；95%置信区间，1.1-15.7；P=0.035）。
结论
我们的数据表明，C/C 变异型的乳腺癌患者可能最常出现多灶性肿瘤。
Zotero 插件